Literature DB >> 32010897

Effective Ankaferd Hemostat Treatment For Severe Intractable Chronic Deep Leg Ulcer Associated With Behçet's Disease.

Rafiye Çiftçiler1, Erdinç Çiftçiler2, İbrahim Haznedaroğlu1.   

Abstract

Ankaferd hemostat (Ankaferd Blood Stopper; ABS) is a pro-hemostatic agent affecting erythrocytes. In this article, we report a 50-year-old male patient who presented with a non-healing leg ulcer for one year. He had a past medical history of Behçet's disease (BD) diagnosed at the age of 29 and therapy was started. Patient's leg ulcer did not respond to any treatment. Topical ABS was applied to the patient's leg ulcer daily. Our experience suggested that local treatment of ABS can be a potentially successful therapy for the management of intractable or incurable chronic ulcers in patients with BD or for other ischemic or vasculitic skin problems.
Copyright © 2019, Turkish League Against Rheumatism.

Entities:  

Keywords:  Ankaferd hemostat; Behçet’s disease; leg ulcer

Year:  2019        PMID: 32010897      PMCID: PMC6974380          DOI: 10.5606/ArchRheumatol.2019.7361

Source DB:  PubMed          Journal:  Arch Rheumatol        ISSN: 2148-5046            Impact factor:   1.472


  15 in total

Review 1.  Behçet's disease.

Authors:  T Sakane; M Takeno; N Suzuki; G Inaba
Journal:  N Engl J Med       Date:  1999-10-21       Impact factor: 91.245

2.  Leg ulcers in Behçet's disease.

Authors:  J-Y Jung; D-Y Kim; D Bang
Journal:  Br J Dermatol       Date:  2007-10-17       Impact factor: 9.302

3.  Haemostatic actions of the folkloric medicinal plant extract Ankaferd Blood Stopper.

Authors:  H Goker; I C Haznedaroglu; S Ercetin; S Kirazli; U Akman; Y Ozturk; H C Firat
Journal:  J Int Med Res       Date:  2008 Jan-Feb       Impact factor: 1.671

Review 4.  Behçet's disease.

Authors:  J B Michelson; F V Chisari
Journal:  Surv Ophthalmol       Date:  1982 Jan-Feb       Impact factor: 6.048

5.  The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria.

Authors: 
Journal:  J Eur Acad Dermatol Venereol       Date:  2013-02-26       Impact factor: 6.166

6.  Protective effects of Ankaferd blood stopper on aspirin-induced oxidative mucosal damage in a rat model of gastric injury.

Authors:  Rukiye Hasgul; Sema Uysal; Hacer Haltas; Sumeyye Akyol; Yasemin Yuksel; Ayse Gurel; Ferah Armutcu
Journal:  Toxicol Ind Health       Date:  2012-10-31       Impact factor: 2.273

7.  Does the application of Ankaferd Blood Stopper rectally have positive effects on the healing of colorectal anastomosis and prevention of anastomotic leakage? An experimental study.

Authors:  Serdar Kuru; Kemal Kismet; Yusuf Murat Bag; Aziz Mutlu Barlas; Mehmet Senes; Murat Durak; Nihat Yumusak; Mustafa Kemal Urhan; Turgut Cavusoglu; Recep Pekcici
Journal:  Biomed Pharmacother       Date:  2017-12-01       Impact factor: 6.529

8.  Successful mesenchymal stem cell treatment of leg ulcers complicated by Behcet disease: A case report and literature review.

Authors:  Yanhong Li; Zhongming Wang; Yi Zhao; Yubin Luo; Wangdong Xu; Tony N Marion; Yi Liu
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

9.  Anti-inflammatory efficiency of Ankaferd blood stopper in experimental distal colitis model.

Authors:  Erdem Koçak; Erdem Akbal; Adnan Taş; Seyfettin Köklü; Gökhan Karaca; Murat Can; Bahadir Kösem; Hüseyin Üstün
Journal:  Saudi J Gastroenterol       Date:  2013 May-Jun       Impact factor: 2.485

10.  On Being a “Physician Patient” with His Own Experimental Therapeutic Drug

Authors:  Rafiye Çiftçiler; İbrahim C. Haznedaroğlu
Journal:  Turk J Haematol       Date:  2018-07-24       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.